July 9, 2018 04:02 AM EDT
R&D
Pharma

Fo­cused on re­build­ing the pipeline, Ax­o­van­t's new crew as­sem­bles an­oth­er pre­clin­i­cal gene ther­a­py deal

John Carroll

Editor & Founder

Just a few weeks af­ter Vivek Ra­maswamy’s Ax­o­vant $AX­ON got a big boost out of its li­cens­ing pact with Ox­ford Bio­Med­ica for what is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

A service from the Financial Times